evidencegaps
Findings

What do systematic reviews say?

Refine by population, intervention, comparison or outcome
More filters
Evidence found and GRADE certainty

2,209 questions · 2,322 findings · 227 reviews · Headline outcomes only

Sort:Best matchNewestHighest certaintyDownload CSV
No studies found 644 · 27.7%GRADE not reported 135 · 5.8%Very low 591 · 25.5%Low 582 · 25.1%Moderate 309 · 13.3%High 61 · 2.6%

Point‐of‐care biomarkers (C‐reactive protein) for infection vs usual care

Clinical recovery · people with acute respiratory infections
2 findings from 1 review

Active drug (etanercept or belimumab) with standard therapy vs placebo + standard care

Remission · adults (age 18 years and older) with GPA ANCA‐associated vasculitis or microscopic polyangiitis (only a subset of patients in one study,…

Active drug (etanercept or belimumab) with standard therapy showed no clear difference in remission (number of patients with remission) compared with standard therapy with placebo (low certainty).

1 finding from 1 review

Active drug (etanercept or belimumab) with standard therapy vs placebo + standard care

Durable remission · adults (age 18 years and older) with GPA ANCA‐associated vasculitis or microscopic polyangiitis (only a subset of patients in one study,…

Active drug (etanercept or belimumab) with standard therapy showed no clear difference in durable remission compared with standard therapy with placebo (low certainty).

1 finding from 1 review

Active drug (etanercept or belimumab) with standard therapy vs placebo + standard care

Major relapse · adults (age 18 years and older) with GPA ANCA‐associated vasculitis or microscopic polyangiitis (only a subset of patients in one study,…

Active drug (etanercept or belimumab) with standard therapy showed no clear difference in major relapse compared with standard therapy with placebo (low certainty).

1 finding from 1 review

Active drug (etanercept or belimumab) with standard therapy vs placebo + standard care

Disease flare · adults (age 18 years and older) with GPA ANCA‐associated vasculitis or microscopic polyangiitis (only a subset of patients in one study,…

Active drug (etanercept or belimumab) with standard therapy showed no clear difference in disease flare compared with standard therapy with placebo (moderate certainty).

1 finding from 1 review

Active drug (etanercept or belimumab) with standard therapy vs placebo + standard care

Any adverse event · adults (age 18 years and older) with GPA ANCA‐associated vasculitis or microscopic polyangiitis (only a subset of patients in one study,…

Active drug (etanercept or belimumab) with standard therapy showed no clear difference in any adverse event compared with standard therapy with placebo (low certainty).

1 finding from 1 review

Active drug (etanercept or belimumab) with standard therapy vs placebo + standard care

Any severe or serious AE (grade 3, 4 or 5) · adults (age 18 years and older) with GPA ANCA‐associated vasculitis or microscopic polyangiitis (only a subset of patients in one study,…

Active drug (etanercept or belimumab) with standard therapy showed no clear difference in any severe or serious AE (grade 3, 4 or 5) compared with standard therapy with placebo (low certainty).

1 finding from 1 review

Active drug (etanercept or belimumab) with standard therapy vs placebo + standard care

Withdrawals due to adverse events · adults (age 18 years and older) with GPA ANCA‐associated vasculitis or microscopic polyangiitis (only a subset of patients in one study,…

Active drug (etanercept or belimumab) with standard therapy may leads to higher any withdrawals due to AE compared with standard therapy with placebo (low certainty).

1 finding from 1 review

Active drug (etanercept or belimumab) with standard therapy vs placebo + standard care

MortalityNumber of participants: 285(2 RCTs) WGET 2005 · adults (age 18 years and older) with GPA ANCA‐associated vasculitis or microscopic polyangiitis (only a subset of patients in one study,…

Active drug (etanercept or belimumab) with standard therapy showed no clear difference in mortalityNumber of participants: 285(2 RCTs) WGET 2005 compared with standard therapy with placebo (low certainty).

1 finding from 1 review

Early active flexion plus controlled passive exercise regimen vs controlled passive exercise regimen following surgery

Functional assessment using a patient reported outcome measure: · participants undergoing rehabilitation following surgery for flexor tendon injuries of the handa
2 findings from 1 review

Early active flexion plus controlled passive exercise regimen vs controlled passive exercise regimen following surgery

Adverse events: participants incurring one or more adverse events · participants undergoing rehabilitation following surgery for flexor tendon injuries of the handa

It is very uncertain whether early active flexion plus controlled passive exercise regimen changes adverse events: participants incurring one or more adverse events compared with early controlled passive exercise regimen (very low certainty).

1 finding from 1 review

Early active flexion plus controlled passive exercise regimen vs controlled passive exercise regimen following surgery

Tendon rupture · participants undergoing rehabilitation following surgery for flexor tendon injuries of the handa

It is very uncertain whether early active flexion plus controlled passive exercise regimen changes adverse event (tendon rupture) compared with early controlled passive exercise regimen (very low certainty).

1 finding from 1 review

Oral methotrexate plus intra‐articular glucocorticoid vs intra‐articular glucocorticoid alone

Sustained clinically inactive diseasec · children and young people with JIA

Oral methotrexate plus intra‐articular glucocorticoid showed no clear difference in sustained clinically inactive diseaseb(12 months) compared with intra‐articular glucocorticoid alone (low certainty).

1 finding from 1 review